Dynavax Technologies Corp. saw its stock price climb by about 9% last week, against a drop in the NASDAQ Biotech Index of just just under 1%. In the last gasp of trading that preceded the Labor Day weekend, Dynavax’s announcement of the cancellation of its FDA Advisory Committee meeting for the HEPLISAV-B (recombinant hepatitis B vaccine) BLA had been described by the analysts from Cowen as "rather cryptic" and greeted with about a 30% stock price drop. (Also see "Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says" - Pink Sheet, 6 September, 2016.)
However, subsequent support from investment bank analysts and the company’s clarification that it still expected the vaccine’s December PDUFA date to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?